Sharon Shacham - Mar 29, 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role: Chief Scientific Officer
Signature: /s/Nancy Smith as Attorney-in-Fact for Sharon Shacham
Stock symbol: KPTI
Transactions as of: Mar 29, 2022
Transactions value $: $0
Form type: 4
Date filed: 3/31/2022, 04:17 PM
Previous filing: Mar 2, 2022
Next filing: Nov 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KPTI	Common Stock	Award	$0	+60K	+6.68%	$0.00	958K	Mar 29, 2022	Direct	F1
holding	KPTI	Common Stock						714K	Mar 29, 2022	By Spouse

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KPTI	Stock Option (right to buy)	Award	$0	+90K		$0.00	90K	Mar 29, 2022	Common Stock	90K	$10.33	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023.
F2	This option was granted on March 29, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.